MedTrace Logo

D-mannose for the Prevention of UTIs in Multiple Sclerosis

NCT02490046 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-07-03

No results posted yet for this study

Summary

This is a study to explore the feasibility of using D-mannose, a commonly used food supplement, in persons with multiple sclerosis reporting recurrent urinary tract infections. Twenty persons with multiple sclerosis (10 patients using catheters and 10 not using catheters) reporting recurrent urinary tract infections will receive D-mannose 1.5 grams twice daily for 16 weeks duration.

This will be explored through:

1. Assessing compliance to a 16-week course of D-mannose
2. Quantifying the number of prescriptions for antibiotics during the 16 weeks course of D-mannose

Conditions

Interventions

DIETARY_SUPPLEMENT

D Mannose

Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.

Sponsors & Collaborators

  • UCLH

    collaborator UNKNOWN

  • University College, London

    lead OTHER

Principal Investigators

  • Jalesh Panicker, MD,FRCP · UCLH NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-10-31
Completion
2015-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490046 on ClinicalTrials.gov